These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 35303065

  • 21. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I, Faubion WA.
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [Abstract] [Full Text] [Related]

  • 22. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
    Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP.
    Inflamm Bowel Dis; 2013 Jun; 19(7):1404-10. PubMed ID: 23665964
    [Abstract] [Full Text] [Related]

  • 23. Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease.
    Kariyawasam VC, Ward MG, Blaker PA, Patel KV, Goel R, Sanderson JD, Irving PM.
    Inflamm Bowel Dis; 2017 Sep; 23(9):1555-1565. PubMed ID: 28786865
    [Abstract] [Full Text] [Related]

  • 24. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
    Luber RP, Dawson L, Munari S, Kariyawasam VC, Martin C, Gibson PR, Sparrow MP, Ward MG.
    J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
    [Abstract] [Full Text] [Related]

  • 25. The safety and tolerability of methotrexate for treating patients with Crohn's disease.
    Chande N, Abdelgadir I, Gregor J.
    J Clin Gastroenterol; 2011 Aug; 45(7):599-601. PubMed ID: 21224737
    [Abstract] [Full Text] [Related]

  • 26. Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease.
    Sequier L, Caron B, Loeuille D, Honap S, Jairath V, Netter P, Danese S, Sibilia J, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2024 Sep; 60(6):686-700. PubMed ID: 39076140
    [Abstract] [Full Text] [Related]

  • 27. Methotrexate for maintenance of remission in Crohn's disease.
    Patel V, Macdonald JK, McDonald JW, Chande N.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD006884. PubMed ID: 19821390
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
    van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri NSM, Mares WGN, Mahmmod N, van Asseldonk DP, Lutgens MWMD, Kuyvenhoven JP, Rietdijk ST, Nissen LHC, Koehestanie P, de Boer NKH, de Jonge R, Bouma G, Bulatović Ćalasan M, Dutch Initiative on Crohn and Colitis (ICC).
    Aliment Pharmacol Ther; 2023 Dec 07; 58(11-12):1151-1162. PubMed ID: 37767910
    [Abstract] [Full Text] [Related]

  • 29. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
    Charpignon C, Beau P.
    Gastroenterol Clin Biol; 2008 Feb 07; 32(2):153-7. PubMed ID: 18343615
    [Abstract] [Full Text] [Related]

  • 30. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
    Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA, LIR!C study group.
    Lancet Gastroenterol Hepatol; 2017 Nov 07; 2(11):785-792. PubMed ID: 28838644
    [Abstract] [Full Text] [Related]

  • 31. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA, McDonald JW, Feagan BG.
    Cochrane Database Syst Rev; 2005 Jan 25; (1):CD003459. PubMed ID: 15674908
    [Abstract] [Full Text] [Related]

  • 32. Methotrexate-induced pneumonitis in a patient with Crohn's disease.
    Margagnoni G, Papi V, Aratari A, Triolo L, Papi C.
    J Crohns Colitis; 2010 Jun 25; 4(2):211-4. PubMed ID: 21122509
    [Abstract] [Full Text] [Related]

  • 33. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA, McDonald JW, Feagan BG.
    Cochrane Database Syst Rev; 2003 Jun 25; (1):CD003459. PubMed ID: 12535475
    [Abstract] [Full Text] [Related]

  • 34. European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis.
    Kopylov U, Katsanos KH, van der Woude CJ, Karmiris K, Hernandez V, Odes S, Papamichael K, Koutroubakis IE, Bojic D, Kaimakliotis I, Fiorino G, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris GJ, Jojic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV.
    Eur J Gastroenterol Hepatol; 2016 Jul 25; 28(7):802-6. PubMed ID: 26894634
    [Abstract] [Full Text] [Related]

  • 35. Thiopurines in inflammatory bowel disease revisited.
    Bär F, Sina C, Fellermann K.
    World J Gastroenterol; 2013 Mar 21; 19(11):1699-706. PubMed ID: 23555158
    [Abstract] [Full Text] [Related]

  • 36. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
    Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G.
    Dig Liver Dis; 2003 Sep 21; 35(9):619-27. PubMed ID: 14563183
    [Abstract] [Full Text] [Related]

  • 37. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M.
    N Engl J Med; 1995 Feb 02; 332(5):292-7. PubMed ID: 7816064
    [Abstract] [Full Text] [Related]

  • 38. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
    González-Lama Y, Suárez C, González-Partida I, Calvo M, Matallana V, de la Revilla J, Magaz M, Bernardo C, Agudo B, Ibarrola P, Relea L, Arévalo J, Vera MI, Abreu L.
    J Crohns Colitis; 2016 Jan 02; 10(1):55-60. PubMed ID: 26520164
    [Abstract] [Full Text] [Related]

  • 39. Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience.
    Suárez Ferrer C, González-Lama Y, González-Partida I, Calvo Moya M, Vera Mendoza I, Matallana Royo V, Arevalo Serrano J, Abreu Garcia L.
    Dig Dis Sci; 2019 Mar 02; 64(3):875-879. PubMed ID: 30542812
    [Abstract] [Full Text] [Related]

  • 40. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
    Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T, DIAMOND2 Study Group.
    J Gastroenterol; 2019 Oct 02; 54(10):860-870. PubMed ID: 31041545
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.